Humalog®

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

HUMALOG® (insulin lispro): Changing From Other Mealtime Insulin Products

Dose adjustment may be needed when transitioning from another insulin to Humalog.

Detailed Information

Dose adjustment may be needed when transitioning from another insulin to IL-100.1

The patient's GC or predisposition to hypoglycemia or hyperglycemia may be affected by changes in insulin

  • strength

  • manufacturer

  • type

  • injection site, or

  • method of administration.1

Any changes to insulin regimen for a patient with DM should be made cautiously and under close medical supervision and the frequency of BG monitoring should be increased.1

Enclosed Prescribing Information

HUMALOG® (insulin lispro injection), for subcutaneous or intravenous use, Lilly

Reference

1. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Glossary

BG = blood glucose

DM = diabetes mellitus

GC = glucose control

IL-100 = Humalog® (insulin lispro injection) 100 units/mL

Date of Last Review: December 13, 2019


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical